These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34980322)

  • 1. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer].
    Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer.
    Wang L; Wu X; Xu W; Gao L; Wang X; Li T
    Front Oncol; 2022; 12():713335. PubMed ID: 35280723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
    Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W
    Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
    Guo ZL; Chen K; Wang XQ; Hu W
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
    Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
    Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
    Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
    Duncan VE; Ping Z; Varambally S; Peker D
    Leuk Lymphoma; 2017 Jan; 58(1):179-184. PubMed ID: 27184221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
    Fujii S; Ito K; Ito Y; Ochiai A
    J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer.
    Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Yaprak Ö; Zorludemir S; Ergin M; Kolsuz İ; Kidi MM
    Rev Assoc Med Bras (1992); 2023; 69(1):153-158. PubMed ID: 36820722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India.
    Rehman AU; Iqbal MA; Sattar RSA; Saikia S; Kashif M; Ali WM; Medhi S; Saluja SS; Husain SA
    Cancer Cell Int; 2020; 20():445. PubMed ID: 32943993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
    Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Neusquen LP; Filassi JR; Fristachi CE; Carvalho KC; Dória MT; Soares Júnior JM; Piato JR
    Rev Bras Ginecol Obstet; 2016 Jun; 38(6):280-6. PubMed ID: 27399922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
    Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
    Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
    Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
    In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of Runt-related Transcription Factor 3 in Human Colon Cancer Cell Line HCT-116 Resistant to 5-Fluorouracil and the Mechanism of Drug Resistance].
    Fan S; Wu XL; Xue J; Xu DD; Han YJ; Li YR; Qu M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):706-715. PubMed ID: 34728031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.
    Nishimura J; Hasegawa J; Ogawa Y; Miwa H; Uemura M; Haraguchi N; Hata T; Yamamoto H; Takemasa I; Mizushima T; Nezu R; Doki Y; Mori M
    Surg Today; 2016 Oct; 46(10):1152-8. PubMed ID: 26711129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.